secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK:        0001314052
Form:       8-K
Filed at:   2022-04-08T23:59:59+00:00
Accession:  0001731122-22-000700
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anavex extends CEO Missling's contract through July 2025; grants 500K options tied to clinical milestones
--------------------------------------------------------------------------------

- CEO Christopher Missling's employment agreement extended to July 5, 2025.
- Base salary increased to $700,000 annually effective July 5, 2022, with target bonus of 20%.
- Grant of 500,000 options vesting upon completion of three clinical trial milestones (Alzheimer’s Phase 2b/3, Parkinson’s trial initiation, Fragile X Phase 2/3 initiation).
- Options exercise price equals closing price on grant date; accelerated vesting upon change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314052/000173112222000700/0001731122-22-000700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314052/000173112222000700/e3692_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-22-000700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer